A. Rouzes, K. Berthoin, and F. Xuereb, Simultaneous determination of the 13 antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in 14 human peripheral blood mononuclear cells by high-performance liquid 15 chromatography-mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, vol.16813, issue.17, pp.209-225, 2004.

M. Ehrhardt, M. Mock, and W. Haefeli, Monitoring of lopinavir and ritonavir in 18 peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and 19 highly sensitive LC/MS/MS assay, J Chromatogr B Analyt Technol Biomed Life Sci, vol.20850, issue.21, pp.249-58, 2007.

S. Azoulay, M. Nevers, and C. Creminon, An enzyme immunoassay for the 22 quantification of plasma and intracellular lopinavir in HIV-infected patients, J Immunol, vol.23295, issue.24, pp.37-48, 2004.

C. Roucairol, S. Azoulay, and M. Nevers, Quantitative Immunoassay To Measure Plasma and Intracellular Atazanavir Levels: Analysis of Drug Accumulation in Cultured T Cells, Antimicrobial Agents and Chemotherapy, vol.51, issue.2, pp.405-416, 2007.
DOI : 10.1128/AAC.00730-06

J. Ford, S. Khoo, and D. Back, The intracellular pharmacology of antiretroviral protease inhibitors, Journal of Antimicrobial Chemotherapy, vol.54, issue.6, pp.982-90, 2004.
DOI : 10.1093/jac/dkh487

M. Boffito, D. Back, and T. Blaschke, Protein Binding in Antiretroviral Therapies, AIDS Research and Human Retroviruses, vol.19, issue.9, pp.825-860, 2003.
DOI : 10.1089/088922203769232629

C. Cropp, S. Yee, and K. Giacomini, Genetic Variation in Drug Transporters in Ethnic Populations, Clinical Pharmacology & Therapeutics, vol.453, issue.3, pp.412-418, 2008.
DOI : 10.1038/clpt.2008.98

G. Minuesa, S. Purcet, and I. Erkizia, Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells, Journal of Pharmacology and Experimental Therapeutics, vol.324, issue.2, pp.558-67, 2008.
DOI : 10.1124/jpet.107.131482

K. Kock, M. Grube, and G. Jedlitschky, Expression of adenosine triphosphate- 37 binding cassette (ABC) drug transporters in peripheral blood cells: relevance for 38 physiology and pharmacotherapy, Abcg2/Bcrp1 mediates the polarized transport of 40 antiretroviral nucleosides abacavir and zidovudine, pp.449-70, 2007.

J. Weiss, J. Rose, and C. Storch, Modulation of human BCRP (ABCG2) activity by anti-HIV drugs, Journal of Antimicrobial Chemotherapy, vol.59, issue.2, pp.238-283, 2007.
DOI : 10.1093/jac/dkl474

M. St-pierre, B. Ugele, and L. Gambling, Mechanisms of drug transfer across 45 the human placenta-a workshop report Cell entry and 47 export of nucleoside analogues, Placenta Virus Res Feb, vol.231075707, issue.2, pp.151-64, 2002.

P. Hoggard and D. Back, Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules, Current Opinion in Infectious Diseases, vol.15, issue.1, 2002.
DOI : 10.1097/00001432-200202000-00002

N. Strazielle, M. Belin, and J. Ghersi-egea, Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters, AIDS, vol.17, issue.10, pp.1473-85, 2003.
DOI : 10.1097/00002030-200307040-00008

H. Izzedine, J. Hulot, and E. Villard, Association between ABCC2 gene 7 haplotypes and tenofovir-induced proximal tubulopathy, J Infect Dis, vol.194, issue.9, pp.8-1481, 2006.

P. Anderson, J. Zheng, and T. King, Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults, AIDS, vol.21, issue.14, pp.1849-54, 200711-09-12.
DOI : 10.1097/QAD.0b013e3282741feb

C. Fletcher, T. King, and L. Bushman, Compartmental kinetics of intracellular 13 tenofovir [abstract n° 754] Conference on retrovi ruses and Opportunistic Infections 14, pp.341-67, 2006.

E. Arner, A. Valentin, and S. Eriksson, Thymidine and 3'-azido-3'-deoxythymidine 16 metabolism in human peripheral blood lymphocytes and monocyte-derived 17 macrophages. A study of both anabolic and catabolic pathways, J Biol Chem, 1992.

C. Gavegnano, E. Fromentin, R. Schinazicenter-for, and A. Research, Lower 20 levels of nucleoside analog triphosphates in primary human macrophages compared 21 to human lymphocytes could impair potency of antiretroviral drugs in human viral 22 reservoirs. HIV DART, 1223.

C. Perno, V. Svicher, and D. Schols, Therapeutic strategies towards HIV-1 infection in macrophages, Antiviral Research, vol.71, issue.2-3, pp.293-300, 2006.
DOI : 10.1016/j.antiviral.2006.05.015

E. Stormer, L. Von-moltke, and M. Perloff, Differential modulation of P- 26 glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase 27 inhibitors in cell culture, Pharmaceutical Research, vol.19, issue.7, pp.1038-1083, 2002.
DOI : 10.1023/A:1016430825740

I. Cascorbi, Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs, Pharmacology & Therapeutics, vol.112, issue.2, pp.457-73, 2006.
DOI : 10.1016/j.pharmthera.2006.04.009

P. Anderson, J. Lamba, and C. Aquilante, Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.4, pp.441-450, 2006.
DOI : 10.1097/01.qai.0000225013.53568.69

E. Meaden, P. Hoggard, and P. Newton, P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals, Journal of Antimicrobial Chemotherapy, vol.50, issue.4, pp.583-591, 2002.
DOI : 10.1093/jac/dkf161

R. Ho, R. Kim, and U. Zanger, Transporters and drug therapy: implications for drug 37 disposition and disease Pharmacogenetics of anti-HIV drugs, Clin Pharmacol Ther Annu Rev Pharmacol Toxicol, vol.7848, issue.40, pp.260-77, 2005.

L. Porte, C. Li, Y. Beique, and L. , The effect of ABCB1 polymorphism on the 41 pharmacokinetics of saquinavir alone and in combination with ritonavir Clin 42 An MDR1-3435 variant is associated 44 with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 45 infected children Intracellular and plasma 47 pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P- 48 glycoprotein expression, Pharmacol Ther Aids Mar Antivir Ther Feb, vol.821995707, issue.441, pp.389-95, 2004.

S. Chaillou, J. Durant, and R. Garraffo, Intracellular Concentration of Protease Inhibitors in HIV-1--Infected Patients: Correlation with MDR-1 Gene Expression and Low Dose of Ritonavir, HIV Clinical Trials, vol.14, issue.4, pp.493-501, 2002.
DOI : 10.1093/carcin/20.3.407

J. Kiser, C. Aquilante, and P. Anderson, Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.47, issue.3
DOI : 10.1097/QAI.0b013e31815e7478

T. Hawkins, W. Veikley, S. Claire, and R. , Intracellular pharmacokinetics 10 of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in 11 patients receiving triple-nucleoside regimens, J Acquir Immune Defic Syndr, 2005.

P. Hoggard, J. Lloyd, and S. Khoo, Zidovudine phosphorylation determined 14 sequentially over 12 months in human immunodeficiency virus-infected patients with 15 or without previous exposure to antiretroviral agents Zidovudine triphosphate and 18 lamivudine triphosphate concentration-response relationships in HIV-infected 19 persons Measurement of intracellular 21 didanosine and tenofovir phosphorylated metabolites and possible interaction of the 22 two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents 23 Chemother, Antimicrob Agents Chemother Aids Clin Pharmacokinet, vol.1645144943, issue.27, pp.976-80, 2000.

J. Moore, E. Acosta, and V. Johnson, Intracellular nucleoside triphosphate 28 concentrations in HIV-infected patients on dual nucleoside reverse transcriptase 29 inhibitor therapy Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma 31 pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR 32 study), Antivir Ther Aids, vol.1218, issue.33, pp.981-987, 2004.

C. Lamotte, R. Landman, and G. Peytavin, Once-daily dosing of saquinavir 34 soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 35 study), Antivir Ther, vol.9, issue.36, pp.247-56, 2004.

M. Rotger, S. Colombo, and H. Furrer, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients, Pharmacogenetics and Genomics, vol.15, issue.1, pp.1-5, 2005.
DOI : 10.1097/01213011-200501000-00001

P. Flynn, J. Rodman, and J. Lindsey, Intracellular pharmacokinetics of once 40 versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents 41 Chemother, pp.3516-3538, 2007.

F. Aweeka, S. Rosenkranz, and Y. Segal, The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine, AIDS, vol.20, issue.14, pp.1833-1874, 2006.
DOI : 10.1097/01.aids.0000244202.18629.36

J. Rodman, P. Flynn, and B. Robbins, Systemic Pharmacokinetics and Cellular Pharmacology of Zidovudine in Human Immunodeficiency Virus Type 1???Infected Women and Newborn Infants, The Journal of Infectious Diseases, vol.180, issue.6, pp.1844-50, 1999.
DOI : 10.1086/315152

M. Barry, S. Khoo, and G. Veal, The effect of zidovudine dose on the 49 formation of intracellular phosphorylated metabolites, AIDS, vol.105707, issue.12, pp.1361-1368, 1996.

J. Kiser, C. Fletcher, and P. Flynn, Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir-Ritonavir in Adolescents and Young Adults with Human Immunodeficiency Virus Infection, Antimicrobial Agents and Chemotherapy, vol.52, issue.2
DOI : 10.1128/AAC.00761-07

S. Djabarouti, D. Breilh, and I. Pellegrin, Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study), Journal of Antimicrobial Chemotherapy, vol.58, issue.5, pp.1090-1093, 2006.
DOI : 10.1093/jac/dkl348

J. Ford, M. Boffito, and A. Wildfire, Intracellular and plasma pharmacokinetics 9 of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human 10 immunodeficiency virus-infected patients The plasma and intracellular 13 steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients, Antimicrob Agents Chemother Crommentuyn KM, vol.489, issue.15, pp.11-2388, 2004.

L. Durand-gasselin, A. Pruvost, and A. Dehee, High levels of zidovudine (AZT) 16 and its intracellular phosphate metabolites in AZT-and AZT-lamivudine-treated 17 newborns of human immunodeficiency virus-infected mothers. Antimicrob Agents 18 Chemother, pp.2555-63, 2008.

L. Wang, J. Begley, S. Claire, and R. , Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV Infection, AIDS Research and Human Retroviruses, vol.20, issue.11, pp.1173-1195, 2004.
DOI : 10.1089/aid.2004.20.1173

M. Harris, D. Back, and S. Kewn, Intracellular carbovir triphosphate levels in patients taking abacavir once a day, AIDS, vol.16, issue.8, pp.1196-1203, 2002.
DOI : 10.1097/00002030-200205240-00021

D. Havlir, C. Tierney, and G. Friedland, In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy, The Journal of Infectious Diseases, vol.182, issue.1, pp.321-326, 2000.
DOI : 10.1086/315683

P. Hoggard, S. Khoo, and M. Barry, Intracellular Metabolism of Zidovudine and Stavudine in Combination, Journal of Infectious Diseases, vol.174, issue.3, pp.671-673, 1996.
DOI : 10.1093/infdis/174.3.671

P. Hoggard, S. Kewn, and M. Barry, Effects of drugs on 2',3'-dideoxy-2',3'- 30 didehydrothymidine phosphorylation in vitro, Antimicrob Agents Chemother, 1997.

A. Pruvost, E. Negredo, and F. Theodoro, A pilot pharmacokinetic study in HIV 33 infected patient receiving tenofovir disoproxil fumarate (TDF): Investigation of 34 systemic and intracellular interaction between TDF and abacavir, lamivudine or 35 lopinavir/ritonavir Early virologic nonresponse to 37 tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects, Antimicrob Agents Chemother J 38 Infect Dis, vol.9192, issue.11, pp.36-106, 2005.

J. Kiser, M. Carten, and C. Aquilante, The effect of lopinavir/ritonavir on the 40 renal clearance of tenofovir in HIV-infected patients, Clin Pharmacol Ther, 2008.

P. Hoggard, S. Sales, and D. Phiboonbanakit, Influence of prior exposure to 43 zidovudine on stavudine phosphorylation in vivo and ex vivo. Antimicrob Agents 44 Chemother, Feb, vol.45, issue.2, pp.577-82, 2001.

C. Katlama, M. Valantin, and S. Matheron, Efficacy and tolerability of 46 stavudine plus lamivudine in treatment-naive and treatment-experienced patients 47 with HIV-1 infection, Ann Intern Med, vol.1295707, issue.7, pp.525-556, 1998.

M. Murphy, O. Hearn, M. Chou, and S. , Fatal Lactic Acidosis and Acute Renal Failure after Addition of Tenofovir to an Antiretroviral Regimen Containing Didanosine, Clinical Infectious Diseases, vol.36, issue.8
DOI : 10.1086/368313

M. Masia, F. Gutierrez, and S. Padilla, Didanosine-Associated Toxicity, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.35, issue.4
DOI : 10.1097/00126334-200404010-00013

P. Barreiro and V. Soriano, Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir, Journal of Antimicrobial Chemotherapy, vol.57, issue.5, pp.806-815, 2006.
DOI : 10.1093/jac/dkl045

M. Perez-elias, S. Moreno, and C. Gutierrez, High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir, AIDS, vol.19, issue.7, pp.695-703, 2005.
DOI : 10.1097/01.aids.0000166092.39317.42

M. Tung, S. Mandalia, and M. Bower, The durability of virological success of 15 tenofovir and didanosine dosed at either 400 or 250 mg once daily, HIV Med, 2005.

T. Holdich, L. Shiveley, and J. Sawyer, Effect of Lamivudine on the plasma and 18 intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse 19 transcriptase inhibitor, in healthy volunteers, Antimicrob Agents Chemother, 2007.

I. Frank, R. Bosch, and S. Fiscus, Activity, safety, and immunological effects 22 of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 23 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307, AIDS Res Hum Retroviruses, vol.2420, issue.9, pp.916-942, 2004.

R. Bakshi, F. Hamzeh, and I. Frank, Effect of Hydroxyurea and Dideoxyinosine on Intracellular 3???-Deoxyadenosine-5???-triphosphate Concentrations in HIV-Infected Patients, AIDS Research and Human Retroviruses, vol.23, issue.11, pp.1360-1365, 2007.
DOI : 10.1089/aid.2007.0078

D. Margolis, A. Heredia, and J. Gaywee, Abacavir and mycophenolic acid, an 29 inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic 30 anti-HIV activity, J Acquir Immune Defic Syndr Aug, vol.1521, issue.5, pp.362-70, 1999.

N. Dixit and A. Perelson, The metabolism, pharmacokinetics and mechanisms 32 of antiviral activity of ribavirin against hepatitis C virus, Cell Mol Life Sci, vol.63, pp.33-40, 2006.

M. Rodriguez-torres, F. Torriani, and V. Soriano, Effect of ribavirin on 35 intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase 36 inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: 37 results of a randomized clinical study, Antimicrob Agents Chemother, vol.49, issue.10, pp.38-3997, 2005.

F. Aweeka, M. Kang, and J. Yu, Pharmacokinetic evaluation of the effects of 40 ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team, HIV Med, vol.418, issue.5, pp.288-94, 2007.

S. Sim, P. Hoggard, and S. Sales, Effect of ribavirin on zidovudine 43 efficacy and toxicity in vitro: a concentration-dependent interaction, AIDS Res Hum, vol.4414, issue.18, pp.1661-1668, 1998.

M. Vogt, K. Hartshorn, and P. Furman, Ribavirin antagonizes the effect of azidothymidine on HIV replication, Science, vol.235, issue.4794, pp.1376-1385, 1987.
DOI : 10.1126/science.2435003

J. Balzarini, C. Lee, and P. Herdewijn, Mechanism of the potentiating effect of 48 ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus, J Biol Chem Nov, vol.152665707, issue.32, pp.21509-21523, 1991.

F. Bani-sadr, F. Carrat, and S. Pol, Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.40, issue.1, pp.47-52, 2005.
DOI : 10.1097/01.qai.0000174649.51084.46

I. Mitochondrial and . Hiv, HCV-coinfected patients receiving ribavirin, Antivir Ther Feb, vol.59, issue.1, pp.133-141, 2004.

J. Ford, M. Boffito, and D. Maitland, Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients, Journal of Antimicrobial Chemotherapy, vol.58, issue.5, 2006.
DOI : 10.1093/jac/dkl379

R. Dicenzo, V. Frerichs, and P. Larppanichpoonphol, Effect of quercetin on the 11 plasma and intracellular concentrations of saquinavir in healthy adults, Pharmacotherapy, vol.1226, issue.9, pp.1255-61, 2006.

S. Khoo, P. Hoggard, and I. Williams, Intracellular accumulation of human 14 immunodeficiency virus protease inhibitors, Antimicrob Agents Chemother, 2002.

E. Vispo, P. Barreiro, and J. Pineda, Low response to pegylated interferon 17 plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir, p.18

B. Stretcher, A. Pesce, and P. Frame, Correlates of zidovudine 20 phosphorylation with markers of HIV disease progression and drug toxicity, Antivir Ther Aids, vol.138, issue.216, pp.429-466, 1994.

D. Back, D. Burger, and C. Flexner, The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.39, issue.Supplement 1, pp.1-23, 2005.
DOI : 10.1097/01.qai.0000168882.67942.3f

C. Fletcher, P. Anderson, and T. Kakuda, Concentration-controlled compared with conventional antiretroviral therapy for HIV infection, AIDS, vol.16, issue.4, pp.551-60, 0278.
DOI : 10.1097/00002030-200203080-00006

H. Drechsler and W. Powderly, Switching Effective Antiretroviral Therapy: A Review, Clinical Infectious Diseases, vol.35, issue.10, pp.1219-1249, 2002.
DOI : 10.1086/343050

M. Kelly, Induction-maintenance antiretroviral strategies to reduce long-term 31 toxicity, J HIV Ther Feb, vol.8, issue.1, pp.11-15, 2003.

F. Maggiolo, M. Airoldi, and H. Kleinloog, Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients, HIV Clinical Trials, vol.5, issue.1, pp.282-92, 2007.
DOI : 10.1128/AAC.45.4.1086-1093.2001

P. Harrigan, R. Hogg, and W. Dong, Predictors of HIV drug-resistance 36 mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy, J 37 Infect Dis Feb, vol.1191, issue.3, pp.339-386, 2005.

R. Braithwaite, S. Shechter, and M. Roberts, Explaining variability in the 39 relationship between antiretroviral adherence and HIV mutation accumulation, p.40

L. Calza, R. Manfredi, and F. Chiodo, Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients, Journal of Antimicrobial Chemotherapy, vol.53, issue.1, pp.10-14, 2004.
DOI : 10.1093/jac/dkh013

N. Bodasing and R. Fox, HIV-associated Lipodystrophy Syndrome: Description and Pathogenesis, Journal of Infection, vol.46, issue.3, pp.149-54, 2003.
DOI : 10.1053/jinf.2002.1102

J. Perez-molina, P. Domingo, and E. Martinez, The role of efavirenz 46 compared with protease inhibitors in the body fat changes associated with highly 47 active antiretroviral therapy, J Antimicrob Chemother, vol.625707, issue.2, pp.234-279, 2008.

J. Mallewa, E. Wilkins, and J. Vilar, HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options, Journal of Antimicrobial Chemotherapy, vol.62, issue.4, p.3, 2008.
DOI : 10.1093/jac/dkn251

D. Nolan and S. Mallal, Complications associated with NRTI therapy: update on 4 clinical features and possible pathogenic mechanisms, Antivir Ther, vol.9, issue.6, pp.5-849, 2004.

G. Dragovic and D. Jevtovic, Nucleoside Reverse Transcriptase Inhibitor Usage and the Incidence of Peripheral Neuropathy in HIV/AIDS Patients, Antiviral Chemistry and Chemotherapy, vol.16, issue.5, pp.281-285, 2003.
DOI : 10.1177/095632020301400507

T. Sinnwell, K. Sivakumar, and S. Soueidan, Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy., Journal of Clinical Investigation, vol.96, issue.1, pp.126-157, 1995.
DOI : 10.1172/JCI118012

R. Yarchoan, J. Pluda, and R. Thomas, Long-term toxicity/activity profile of 13 2',3'-dideoxyinosine in AIDS or AIDS-related complex, Lancet, vol.336, issue.8714, pp.14-526, 1990.

K. Brogan and S. Zell, Hematologic toxicity of zidovudine in HIV-infected 16 patients, Am Fam Physician, vol.41, issue.5, pp.1521-1529, 1990.

S. Gupta, Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting System, AIDS Patient Care and STDs, vol.22, issue.2, pp.99-103, 2008.
DOI : 10.1089/apc.2007.0052

D. Clifford, S. Evans, and Y. Yang, Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals, Annals of Internal Medicine, vol.143, issue.10, pp.714-735, 2005.
DOI : 10.7326/0003-4819-143-10-200511150-00008

L. Martin-carbonero, M. Nunez, and J. Gonzalez-lahoz, Incidence of liver 23 injury after beginning antiretroviral therapy with efavirenz or nevirapine, HIV Clin, vol.244, issue.2, pp.115-135, 2003.

S. Patel, S. Johnson, and S. Belknap, Serious adverse cutaneous and 26 hepatic toxicities associated with nevirapine use by non-HIV-infected individuals, p.27

H. Knobel, A. Guelar, and M. Montero, Risk of side effects associated with the use of nevirapine in treatment-na??ve patients, with respect to gender and CD4 cell count, HIV Medicine, vol.19, issue.1, pp.14-22, 2008.
DOI : 10.1111/j.1468-1293.2008.00513.x

A. Carr, K. Samaras, and D. Chisholm, Pathogenesis of HIV-1-protease 32 inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. 33 Lancet, pp.1881-1884, 1998.

P. Andre, M. Groettrup, and P. Klenerman, An inhibitor of HIV-1 protease 35 modulates proteasome activity, antigen presentation, and T cell responses, Proc Natl, p.36

J. Sakai and R. Rawson, The sterol regulatory element-binding protein pathway: control of lipid homeostasis through regulated intracellular transport, Current Opinion in Lipidology, vol.12, issue.3, pp.261-267, 2001.
DOI : 10.1097/00041433-200106000-00004

H. Murata, P. Hruz, and M. Mueckler, The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy, Journal of Biological Chemistry, vol.275, issue.27, pp.20251-20255, 2000.
DOI : 10.1074/jbc.C000228200

G. Moyle, Mechanisms of HIV and nucleoside reverse transcriptase inhibitor 43 injury to mitochondria, Antivir Ther, vol.10, issue.2, pp.47-52, 2005.

E. Capparelli, J. Englund, and J. Connor, Population pharmacokinetics 45 and pharmacodynamics of zidovudine in HIV-infected infants and children, J Clin Feb, vol.4643, issue.2, pp.133-173, 2003.

F. Mentré, S. Escolano, and B. Diquet, Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity, European Journal of Clinical Pharmacology, vol.I, issue.2, p.49
DOI : 10.1007/BF00315509